Английская Википедия:Brofaromine
Шаблон:Short description Шаблон:Drugbox
Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy.[1] The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.[2]
Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants.
Pharmacology
Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.
See also
References
Шаблон:Antidepressants Шаблон:Anxiolytics Шаблон:Monoamine metabolism modulators
- ↑ US Patent 4210655
- ↑ Шаблон:Cite journal Free full text
- Английская Википедия
- Abandoned drugs
- Antidepressants
- Anxiolytics
- Monoamine oxidase inhibitors
- Reversible inhibitors of MAO-A
- Hydroquinone ethers
- Bromoarenes
- Benzofuran ethers at the benzene ring
- 4-Piperidinyl compounds
- Serotonin reuptake inhibitors
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии
